Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by kuatoliveson Aug 03, 2016 12:20pm
77 Views
Post# 25106644

RE:RE:RE:RE:RE:RE:RE:RE:History will tell you, this is the time to.....

RE:RE:RE:RE:RE:RE:RE:RE:History will tell you, this is the time to.....One thing I learned from the Tribute saga is, and I hope I have some capital left to apply this wisdom, is to be leery about excesive insider ownership percentages. People often laud them as a source of stability, but in the case of Tribute, there was nothing to stop them from selling cheap so they could make a quick buck.  Hindsight is 20/20.

I like to think Monday was the smart money moving in (insiders, etc) in anticpation of Yosprala approval, but we'll see. I have never been one to fear cutting my losses and running (like I did with Merus), and would have put my money some place else where I to see a better opportunity in specialty pharma, but I've yet to see it.  At most one more month and we'll cross the last hurdle before we start to see how the revenue growth story takes shape (or we get blasted back into the stone age).




<< Previous
Bullboard Posts
Next >>